Page 5,007«..1020..5,0065,0075,0085,009..5,0205,030..»

Out With the Old, In With the New in Treating MS

Posted: Published on August 1st, 2013

By Ryan Guenette - July 31, 2013 | Tickers: BIIB, NVS, PFE, SNY, TEVA | 0 Comments Ryan is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Hidden beneath all the numbers and metrics in Biogen Idec's(NASDAQ: BIIB) recent earnings reportis a key confirmation of a shifting market in the treatment of multiple sclerosis. This alteration could yield billions of dollars for companies positioned to take advantage of it. What Happened On July 25, Biogen reported second-quarter financial results. Earnings of $2.30 per share and revenue of $1.7 billion both trumped estimates, while the company's higher guidance fueled investors'optimism regarding the company's future.However, neither development could steal the report's spotlight away from the unexpected success of the companys new multiple sclerosis oral drug, Tecfidera. The drug generated sales of $192 million in the quarter, more than double what the Street expected. A Coming Revolution in MS Treatment Contrary to most current multiple sclerosistreatments , Tecfidera is a pill, not an injection. The treatments which currently dominate this $14.4 billion global market-- Avonex (Biogen), Copaxone (Teva), Tysabri (Biogen), Rebif (Pfizer & EMD Sereno) -- are all injections. … Continue reading →

Posted in MS Treatment | Comments Off on Out With the Old, In With the New in Treating MS

Addition To Ruvo Center's Ms Staff Expected To Improve Research, Treatment Options

Posted: Published on August 1st, 2013

The Cleveland Clinic Lou Ruvo Center for Brain Health, its services for multiple sclerosis strained by a heavy patient load, has expanded its MS staff. That means fewer patients will end up in hospital emergency rooms for expensive treatment. The expansion also allows the clinic to start participating in two international trials in the next two months, according to Dr. Timothy West, director of the MS program. Physician/researcher Dr. Le Hua and social worker Joanne Fairchild will join him in helping patients with the neuromuscular disorder. One of the trials will study the drug Siponimod, designed to slow or stop progression of the most severe form of the disease. About half of the people with MS end up with secondary progressive multiple sclerosis, the most severe form of the disease and one we cant really treat, so the patient goes steadily downhill, West said. This is a very important trial to me on both a professional and personal level. My mother has secondary progressive multiple sclerosis, as do far too many of my patients. The other drug trial involves the oral medication Gilenya, already used by patients in earlier stages of the disease. Though data suggest it has neuro-protective effects, … Continue reading →

Posted in MS Treatment | Comments Off on Addition To Ruvo Center's Ms Staff Expected To Improve Research, Treatment Options

Repligen Reports Second Quarter 2013 Financial Results

Posted: Published on August 1st, 2013

- Product Revenue Grows 12% for the Quarter on Record Bioprocessing Sales -- Net Income Grows 189% to $4.5 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN) today reported financial results for the second quarter ended June 30, 2013. Below are the Company's financial and business highlights for the second quarter of 2013, financial guidance for the year and dial-in numbers for today's conference call. Second Quarter 2013 Financial Highlights Operating expenses for the three-month period ended June 30, 2013 were $11.4 million compared to $14.2 million for the same period in 2012, a decrease of $2.8 million or 20%. This decrease was driven by across-the-board reductions in operating expenses during the second quarter of 2013 compared to the same period in 2012. Cost of product revenue decreased by $2.0 million or 28%; research and development (R&D) expense (including therapeutic program related expense) decreased by $600,000 or 21%; and sales, general and administrative (SG&A) expense decreased by $294,000 or 9%. The reductions in R&D and SG&A expense were primarily due to lower spending on clinical development programs as a result of the Company's … Continue reading →

Comments Off on Repligen Reports Second Quarter 2013 Financial Results

ViroPharma Announces Second Quarter 2013 Financial Results

Posted: Published on August 1st, 2013

EXTON, Pa., Aug. 1, 2013 /PRNewswire/ --VIROPHARMA INCORPORATED (VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012. The increase in net sales quarter over quarter was driven by the commercial product growth of both Cinryze in the U.S. and higher European product sales. During the second quarter of 2013 U.S. Cinryze net sales grew by 22 percent over the second quarter of 2012 to $91 million. The quarterly U.S. Cinryze sales reflect $96 million of patient demand offset by approximately $5 million of wholesaler channel inventory drawdown. The patient demand represents an increase of approximately $5 million from the $91 million of patient demand reported in the first quarter of 2013. "The second quarter of 2013 represented a period of strong commercial execution coupled with significant progress in our clinical development pipeline, despite this morning's news related to our combination efforts with Halozyme," stated Vincent Milano, ViroPharma's chief executive officer. "In addition to the positive maribavir interim data update we shared last month and the continued advancement of enrollment in the two studies, we … Continue reading →

Comments Off on ViroPharma Announces Second Quarter 2013 Financial Results

The American Academy of Anti-aging Medicine (A4M) to Hold Four-day Continuing Medical Education Conference in Boston, MA

Posted: Published on August 1st, 2013

Boca Raton, FL (PRWEB) July 31, 2013 The American Board of Anti-Aging and Regenerative Medicine (ABAARM) exams will be held during this event. Also, physicians have the opportunity to sit for The American Board of Anti-Aging Health Practitioners (ABAAHP) written exam as well. The American Academy of Anti-Aging Medicines (A4M) Fellowship in Anti-Aging and Regenerative Medicine will host several modules including Module IV: Nutrition and Metabolism; Module VIII: Lab Fundamentals and Cancer Therapies; Module XVI (C): Cardiovascular; and The Fellowship in Integrative Cancer will host Module VII: Dietary Treatments of Cancer. Some learning objectives for Module IV include learning about nutritional depletions caused by medications, nutritions role and impact on optimal health in aging patients, new treatment plans for osteoporosis and amino acid deficiencies, and how physical, psychological and spiritual health relate to metabolic and anti-aging medicine, among other lessons. Module VIII attendees will learn advanced integrative approaches to cancer therapies, nutritional support for athletes, how nutrients affect psychiatric illness treatments, and new protocols for advanced stage cancers. Module XVI (C) will teach its participants nutritional and dietary therapies for prevention and treatment of cardiovascular disease, as well as sex hormone balance and function in regards to cardiovascular health in … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on The American Academy of Anti-aging Medicine (A4M) to Hold Four-day Continuing Medical Education Conference in Boston, MA

Dr. Donald Kohn Discusses Stem Cell Research Breakthrough for Sickle Cell Disease – Video

Posted: Published on August 1st, 2013

Dr. Donald Kohn Discusses Stem Cell Research Breakthrough for Sickle Cell Disease Dr. Donald Kohn, researcher at the Eli Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and Jonsson Comprehensive Cancer Center ... By: UCLAJCCC … Continue reading →

Posted in Stem Cell Research | Comments Off on Dr. Donald Kohn Discusses Stem Cell Research Breakthrough for Sickle Cell Disease – Video

An essential step in growing human livers

Posted: Published on August 1st, 2013

I bring great news from the world of stem-cell research. Japanese scientists published a paper in the science journal Nature on July 3rd demonstrating proof of concept that a working human liver can be built in the laboratory from stem cells. The work was carried out by a team led by Takanori Takebe at Yokohama City University. This work is the first step in growing replacement livers from stem cells for transplants. There is a serious scarcity of livers for transplant. In 2011 more than 16,000 people in the US were on a waiting list for a liver transplant, 5,805 transplants were carried out and 2,938 people either died that year waiting for a new liver or became too ill to remain on the list. It will take about 10 years, all going well, to develop the initial work of Takebes team before livers grown from stem cells can be transplanted into humans. Im particularly pleased by Takebes work because this breakthrough was made using human-induced pluripotent stem cells (IPSC) and human adult stem cells derived from umbilical cords. No ethical problems necessarily attend the use of such stem cells unlike with human embryonic stem cells whose preparation entails killing … Continue reading →

Posted in Stem Cell Research | Comments Off on An essential step in growing human livers

International Stem Cell Corporation to Host Second Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on …

Posted: Published on August 1st, 2013

CARLSBAD, CA--(Marketwired - Aug 1, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, August 9, 2013 to discuss its financial results for the three and six months ended June 30, 2013. Dr. Simon Craw, Executive Vice President and Mr. Jay Novak, Interim Chief Financial Officer of International Stem Cell will host the conference call. To attend the call, please use the dial in information below: Date: Friday, August 9, 2013 Time: 11:00 a.m. Eastern Time Conference Line (U.S.): 1-877-317-6776 International Dial-In: 1-412-317-6776 Conference ID: 10032411 Webcast: http://webcast.mzvaluemonitor.com/Cover.aspx?PlatformId=1545 Please dial in at least 10-minutes before the call to ensure timely participation. A playback of the call will be available until 11:00 a.m. ET on August 16, 2013. To listen, call 1-877-344-7529 within the United States or 1-412-317-0088 when calling internationally. Please use the replay pin number 10032411. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the … Continue reading →

Posted in Stem Cell Research | Comments Off on International Stem Cell Corporation to Host Second Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on …

France’s top court approves stem cell research law

Posted: Published on August 1st, 2013

PARIS (Reuters) - France's top court approved a law on Thursday making it easier to conduct research on human embryos and stem cells as long as strict rules are followed to prevent cloning. Predominantly Roman Catholic France has until now had tough curbs on embryonic stem cell research under a 2011 law that only allows it with the explicit approval from the national biomedicine agency. Under a new law approved this month with majority backing from the governing Socialists and their allies, the agency's approval is no longer essential, although strict regulations must be followed to conduct such research in France. The Constitutional Council said it had approved the law, rejecting a last-ditch appeal by conservative lawmakers to get it thrown out. Stem cells are the body's mother cells and can self-renew or multiply while maintaining the ability to transform into any type of cell. Researchers around the world have been studying stem cells from various sources for more than a decade, hoping to capitalize on their ability to transform into a wide variety of other kinds of cell to treat a range of health conditions. View post: France’s top court approves stem cell research law … Continue reading →

Posted in Stem Cell Research | Comments Off on France’s top court approves stem cell research law

Top French court backs stem-cell research

Posted: Published on August 1st, 2013

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just … Continue reading →

Posted in Stem Cell Research | Comments Off on Top French court backs stem-cell research

Page 5,007«..1020..5,0065,0075,0085,009..5,0205,030..»